Rebif®
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clinically Isolated Syndrome
Conditions
Clinically Isolated Syndrome
Trial Timeline
Oct 1, 2005 → Nov 1, 2008
NCT ID
NCT00287079About Rebif®
Rebif® is a phase 3 stage product being developed by Merck for Clinically Isolated Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00287079. Target conditions include Clinically Isolated Syndrome.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01791244 | Approved | Completed |
| NCT00287079 | Phase 3 | Completed |